Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature

Bibliography

• DODGE JA, MORISON S, LEWIS PA et al.: Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch. Dis. Child. (1997) 77(6):493-496.
   PubMed Web of Science ®Google Scholar
• GILLIGAN PH: Cystic Fibrosis in Adults. Lippincot-Raven, Philadelphia, USA (1999).
   Google Scholar
• CYSTIC FIBROSIS FOUNDATION: Patient Registry 2003 Annual Report, Bethesda, Maryland (2003).
   Google Scholar
• KNOWLES MR, GILLIGAN PH, BOUCHER RC: Principles and Practice of Infectious Diseases, 6th edn. Elsevier, Churchill, Livingstone, Philadelphia, USA (2005).
   Google Scholar
• AL-ALOUL M, CRAWLEY J, WINSTANLEY C et al.: Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax (2004) 59(4):334-336.
   PubMed Web of Science ®Google Scholar
• ELKINS MR, ROBINSON M, ROSE BR et al.: A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. (2006) 354(3):229-240.
   PubMed Web of Science ®Google Scholar
• TRAMPER-STRANDERS GA, WOLFS TF, FLEER A, KIMPEN JL, VAN DER ENT CK: Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr. Infect. Dis. J. (2007) 26(1):8-12.
   PubMed Web of Science ®Google Scholar
• CLEMENT A, TAMALET A, LEROUX E et al.: Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax (2006) 61(10):895-902.
   PubMed Web of Science ®Google Scholar
• PATHOGENESIS CORP.: TOBI®: tobramycin solution for inhalation. Technical Monograph, International edn (2000).
   Google Scholar
• NEU HC: Tobramycin: an overview. J. Infect. Dis. (1976) 134(Suppl.):S3-S19.
   Web of Science ®Google Scholar
• DORING G, CONWAY SP, HEIJERMAN HG et al.: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. (2000) 16(4):749-767.
   PubMed Web of Science ®Google Scholar
• RYAN G, MUKHOPADHYAY S, SINGH M: Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev (2003) 3:CD001021.
   Google Scholar
• GIBSON RL, RETSCH-BOGART GZ, OERMANN C et al.: Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. (2006) 41(7):656-665.
   PubMed Web of Science ®Google Scholar
• BROGDEN RN, PINDER RM, SAWYER PR, SPEIGHT TM, AVERY GS: Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs (1976) 12(3):166-200.
   PubMed Web of Science ®Google Scholar
• CLAY MM, CLARKE SW: Wastage of drug from nebulisers: a review. J. R. Soc. Med. (1987) 80(1):38-39.
   PubMed Web of Science ®Google Scholar
• LE CONTE P, POTEL G, PELTIER P et al.: Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis (1993) 147(5):1279-1282.
   PubMedGoogle Scholar
• GELLER DE, PITLICK WH, NARDELLA PA, TRACEWELL WG, RAMSEY BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest (2002) 122(1):219-226.
   PubMed Web of Science ®Google Scholar
• FREEMAN CD, NICOLAU DP, BELLIVEAU PP, NIGHTINGALE CH: Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J. Antimicrob. Chemother. (1997) 39(6):677-686.
   PubMed Web of Science ®Google Scholar
• GELLER DE, ROSENFELD M, WALTZ DA, WILMOTT RW: Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest (2003) 123(1):28-36.
   PubMed Web of Science ®Google Scholar
• LEVY J, SMITH AL, KENNY MA, RAMSEY B, SCHOENKNECHT FD: Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J. Infect. Dis. (1983) 148(6):1069-1076.
   PubMed Web of Science ®Google Scholar
• MENDELMAN PM, SMITH AL, LEVY J et al.: Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis (1985) 132(4):761-765.
   PubMed Web of Science ®Google Scholar
• COONEY GF, LUM BL, TOMASELLI M, FIEL SB: Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. (1994) 34(3):255-259.
   PubMed Web of Science ®Google Scholar
• NOVARTIS PHARMACEUITCAL CORP.: TOBI® (tobramycin inhalation solution) prescribing information. Novartis Pharmaceuitcal Corp., Quebec, Canada (2006).
   Google Scholar
• WIKLER MA, COCKERILL FR, CRAIG WA et al.: Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. Clinical and Laboratory Standards Institute Information (2006) M100-S16:112-113.
   Google Scholar
• SHAWAR RM, MACLEOD DL, GARBER RL et al.: Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. (1999) 43(12):2877-2880.
   PubMedGoogle Scholar
• BURNS JL, EMERSON J, STAPP JR et al.: Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. (1998) 27(1):158-163.
   PubMed Web of Science ®Google Scholar
• MOROSINI MI, GARCIA-CASTILLO M, LOZA E et al.: Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J. Clin. Microbiol. (2005) 43(9):4480-4485.
   PubMed Web of Science ®Google Scholar
• BURNS JL, VAN DALFSEN JM, SHAWAR RM et al.: Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. (1999) 179(5):1190-1196.
   PubMed Web of Science ®Google Scholar
• RAMSEY BW, PEPE MS, QUAN JM et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. (1999) 340(1):23-30.
   PubMed Web of Science ®Google Scholar
• MOSS RB: Administration of aerosolized antibiotics in cystic fibrosis patients. Chest (2001) 120(3 Suppl.):107S-113S.
   PubMed Web of Science ®Google Scholar
• HODSON ME, GALLAGHER CG, GOVAN JR: A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. (2002) 20(3):658-664.
   PubMed Web of Science ®Google Scholar
• MACLUSKY IB, GOLD R, COREY M, LEVISON H: Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Pulmonol. (1989) 7(1):42-48.
   PubMed Web of Science ®Google Scholar
• SMITH AL, RAMSEY BW, HEDGES DL et al.: Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmonol. (1989) 7(4):265-271.
   PubMed Web of Science ®Google Scholar
• STEINKAMP G, TUMMLER B, GAPPA M et al.: Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr. Pulmonol. (1989) 6(2):91-98.
   PubMed Web of Science ®Google Scholar
• RAMSEY BW, DORKIN HL, EISENBERG JD et al.: Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. (1993) 328(24):1740-1746.
   PubMed Web of Science ®Google Scholar
• CAMPBELL PW III, SAIMAN L: Use of aerosolized antibiotics in patients with cystic fibrosis. Chest (1999) 116(3):775-788.
   PubMedGoogle Scholar
• MURPHY TD, ANBAR RD, LESTER LA et al.: Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol. (2004) 38(4):314-320.
   PubMed Web of Science ®Google Scholar
• GIBSON RL, EMERSON J, MCNAMARA S et al.: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. (2003) 167(6):841-849.
   PubMed Web of Science ®Google Scholar
• DORING G, HOIBY N: Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. (2004) 3(2):67-91.
   PubMedGoogle Scholar
• WOOD DM, SMYTH AR: Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev (2006) (1):CD004197.
   Google Scholar
• BARKER AF, COUCH L, FIEL SB et al.: Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. (2000) 162(2 Pt 1):481-485.
   PubMed Web of Science ®Google Scholar
• SCHEINBERG P, SHORE E: A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest (2005) 127(4):1420-1426.
   PubMed Web of Science ®Google Scholar
• HAGERMAN JK, HANCOCK KE, KLEPSER ME: Aerosolised antibiotics: a critical appraisal of their use. Expert Opin. Drug Deliv. (2006) 3(1):71-86.
   PubMedGoogle Scholar
• BILTON D, HENIG N, MORRISSEY B, GOTFRIED M: Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of pseudomonas aeruginosa nfection in Adult Bronchiectasis. Chest (2006) 130(5):1503-1510.
   PubMed Web of Science ®Google Scholar
• AHYA VN, DOYLE AM, MENDEZ JD et al.: Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J. Heart Lung Transplant. (2005) 24(7):932-935.
   PubMed Web of Science ®Google Scholar
• EDSON RS, BREY RH, MCDONALD TJ et al.: Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin. Proc. (2004) 79(9):1185-1191.
   PubMed Web of Science ®Google Scholar
• CANNELLA CA, WILKINSON ST: Acute renal failure associated with inhaled tobramycin. Am. J. Health Syst. Pharm. (2006) 63(19):1858-1861.
   PubMed Web of Science ®Google Scholar
• PATATANIAN L: Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Pediatr. Infect. Dis. J. (2006) 25(3):276-278.
   PubMed Web of Science ®Google Scholar
• HOFFMANN IM, RUBIN BK, ISKANDAR SS et al.: Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr. Pulmonol. (2002) 34(5):375-377.
   PubMed Web of Science ®Google Scholar
• PROBER CG, WALSON PD, JONES J: Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics (2000) 106(6):E89.
   PubMed Web of Science ®Google Scholar
• MACLEOD DL, NELSON LE, SHAWAR RM et al.: Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J. Infect. Dis. (2000) 181(3):1180-1184.
   PubMed Web of Science ®Google Scholar
• LIPUMA JJ: Microbiological and immunologic considerations with aerosolized drug delivery. Chest (2001) 120(3 Suppl.):118S-123S.
   Web of Science ®Google Scholar